Diltiazem Dosing in Single Functioning Kidney
For a patient with a single functioning kidney, extended-release diltiazem should be initiated at 120 mg once daily and titrated cautiously to a maximum of 360 mg once daily based on blood pressure response and tolerability, with no specific dose reduction required solely for having one kidney unless renal function is significantly impaired.
Dosing Algorithm
Initial Dosing
- Start with 120 mg once daily of extended-release formulation 1, 2
- The standard immediate-release starting dose is 30 mg four times daily, but extended-release formulations allow for once-daily dosing with improved compliance 2, 3
Titration Strategy
- Increase gradually every 1-2 weeks based on response 2
- Target dose range: 120-360 mg daily for hypertension 1, 4
- For rate control in atrial fibrillation: 120-360 mg daily in divided doses 4
- Maximum dose: 360 mg daily for extended-release formulations 1
Renal Function Considerations
Critical distinction: Having a single functioning kidney does not automatically require dose adjustment unless there is actual renal impairment (reduced GFR).
- If GFR ≥60 mL/min: No dose adjustment needed 5, 6
- If GFR 30-60 mL/min: Use standard dosing with careful monitoring 7
- If GFR <30 mL/min: Initiate at lower doses and titrate with particular caution 2
The evidence shows diltiazem does not significantly affect renal function even with prolonged use. A study of hypertensive patients with creatinine clearances of 64-153 mL/min showed that diltiazem 240 mg daily maintained stable plasma creatinine, creatinine clearance, and GFR over six weeks 7.
Formulation Selection
Extended-release formulations are preferred for patients with renal considerations:
- Sustained-release 120 mg twice daily provides stable plasma concentrations and improved tolerability, particularly beneficial in patients requiring careful hemodynamic monitoring 8
- Once-daily formulations (120-480 mg) are effective and maintain 24-hour blood pressure control 3, 9
Monitoring Requirements
Before Initiation
- Measure serum creatinine and calculate GFR
- Baseline blood pressure and heart rate
- Assess for heart failure or significant cardiac dysfunction 1, 10
During Titration
- Monitor blood pressure and heart rate at each dose increase
- Check renal function if GFR <60 mL/min or if patient has diabetes/CKD 6
- Watch for symptomatic hypotension or bradycardia 1, 10
Maintenance Monitoring
- Periodic blood pressure checks
- Annual renal function assessment if baseline GFR <60 mL/min
- Monitor for peripheral edema (dose-related side effect) 1
Important Safety Considerations
Contraindications and Cautions
- Avoid in decompensated heart failure with reduced ejection fraction 1, 11
- Use caution if systolic BP <140 mmHg at baseline (higher risk of hypotension) 12
- Do not combine with beta-blockers without careful monitoring due to increased bradycardia/heart block risk 1, 10
- Avoid concurrent use with other AV nodal blocking agents 10
Drug Interactions
Diltiazem is a CYP3A4 substrate and moderate inhibitor 1:
- Monitor digoxin levels if used concurrently
- Adjust statin doses if needed (increased myopathy risk)
- Be cautious with other CYP3A4-interacting medications
Specific Renal Disease Context
In end-stage renal disease patients on hemodialysis with coronary artery disease, sustained-release diltiazem 240 mg daily (120 mg twice daily) was both effective and well-tolerated, with improved safety compared to immediate-release formulations 8. This suggests that even in severe renal impairment, therapeutic doses can be achieved safely with appropriate formulation selection.
Clinical Pearls
- Single kidney ≠ automatic dose reduction: Adjust based on actual GFR, not kidney number
- Sustained-release formulations provide more stable drug levels and better tolerability
- Start low, go slow if GFR <30 mL/min or multiple comorbidities present
- Diltiazem does not accumulate significantly in renal impairment compared to other cardiovascular drugs 2
- The drug is 70-80% protein bound with extensive hepatic metabolism, making it relatively safe in renal disease 2